Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma-Reference-Cited by-同舟云学术

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Published:2020-11-06 Issue:1 Volume:112 Page:305-313
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ye Dingwei¹,Liu Jiyan²,Zhou Aiping³,Zou Qing⁴,Li Hanzhong⁵,Fu Cheng⁶,Hu Hailong⁷,Huang Jian⁸,Zhu Shaoxing⁹,Jin Jie¹⁰,Ma Lulin¹¹,Guo Jianming¹²,Xiao Jun¹³,Park Se Hoon¹⁴,Zhang Dahong¹⁵,Qiu Xiusong¹⁶,Bao Yuanyuan¹⁶,Zhang Lilin¹⁶,Shen Wei¹⁶,Bi Feng²

Affiliation:

1. Department of Urology Fudan University Shanghai Cancer Center Shanghai China

2. Department of Medical Oncology West China Hospital Sichuan University Chengdu China

3. Department of Medical Oncology Chinese Academy of Medical Sciences & Peking Union Medical CollegeCancer Institute & Hospital Beijing China

4. Department of Medical Oncology Jiangsu Cancer Hospital Nanjing China

5. Department of Urology Peking Union Medical College Hospital Beijing China

6. Department of Urological Surgical Oncology Liaoning Cancer Hospital & Institute Shenyang, Liaoning China

7. Department of Urology The Second Hospital of Tianjin Medical University Tianjin China

8. Department of Urology Sun Yat‐Sen Memorial Hospital Sun Yat‐sen University Guangzhou China

9. Department of Medical Oncology Zhejiang Cancer Hospital Zhejiang China

10. Department of Urology Peking University First Hospital Beijing China

11. Department of Urology Peking University Third Hospital Beijing China

12. Department of Urology Zhongshan Hospital Fudan University Shanghai China

13. Department of Urology Anhui Provincial Hospital Hefei China

14. Department of Medicine Division of Hematology‐Oncology Samsung Medical Center Sungkyunkwan University Seoul South Korea

15. Department of Urology Zhejiang Provincial People’s Hospital Zhejiang China

16. Department of Medical Oncology BeiGene (Beijing) Co., Ltd Beijing China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14681

Reference25 articles.

1. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

2. Update of systemic immunotherapy for advanced urothelial carcinoma;Gartrell BA;Urol Oncol,2017

3. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

4. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

5. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights into immune cells modulation of tumor resistance;Critical Reviews in Oncology/Hematology;2024-10

2. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

3. Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial;Nature Cancer;2024-09-10

4. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial;Journal of Thoracic Oncology;2024-07

5. The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis;Technology and Health Care;2024-06-27